Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 5:52 PM ET


Company Overview of Catalyst Biosciences, Inc.

Company Overview

Catalyst Biosciences, Inc., a clinical-stage company, focuses on the development of catalytic biopharmaceutical products based on engineered human proteases. It focuses on drug discovery for hemostasis, hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. The company develops FVIIa, an enzyme that initiates blood clotting; FIX, a recombinant human factor IX for treating acute bleeding episodes in hemophilia B patients; and FXa, a pro-coagulant and bypass agent to control bleeding during surgery and trauma for hemophilia inhibitor patients and general population. It develops drugs for ischemia reperfusion inj...

260 Littlefield Avenue

South San Francisco, CA 94080-7019

United States

Founded in 2002





Key Executives for Catalyst Biosciences, Inc.

Chief Executive Officer and Director
Age: 54
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.

Catalyst Biosciences, Inc. Key Developments

Catalyst Biosciences, Inc., Targacept, Inc. - M&A Call

To discuss proposed merger between the two companies

Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM

Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Nassim Usman, Chief Executive Officer and Director.

Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration

Catalyst Biosciences, Inc. and Isu Abxis announced the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. Under the terms of the collaboration, Isu Abxis will use its biologics manufacturing and development expertise to advance FIX-NG through preclinical and Phase 1 studies and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an upfront licensing fee and milestone payments through the end of the Phase 1 clinical trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.

Similar Private Companies By Industry

Company Name Region
Analytical Stem Cell Corp. United States
AntiCancer, Inc. United States
ZeaKal Inc. United States
Adult Stem Cell Corporation of America, Inc. United States
Evolutionary Genomics, Inc. and EG I, LLC United States

Recent Private Companies Transactions

March 5, 2015
Targacept, Inc.
Private Placement
January 22, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Catalyst Biosciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at